A 6-month, multicenter, non-interventional Study to evaluate the Effectiveness and Quality of life impact of the Insulin glargine/Lixisenatide fixed ratio combination in patients with type 2 diabetes mellitus uncontrolled with basal insulin + metformin ± SU: an observational study
Latest Information Update: 22 Nov 2021
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SEQIL
- Sponsors Sanofi
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.
- 11 Aug 2021 New trial record